scispace - formally typeset
R

Ryan Zarychanski

Researcher at University of Manitoba

Publications -  230
Citations -  12857

Ryan Zarychanski is an academic researcher from University of Manitoba. The author has contributed to research in topics: Randomized controlled trial & Medicine. The author has an hindex of 48, co-authored 193 publications receiving 9665 citations. Previous affiliations of Ryan Zarychanski include Winnipeg Regional Health Authority & McGill University.

Papers
More filters
Journal ArticleDOI

The benefits of 24/7 in-house intensivist coverage for prolonged-stay cardiac surgery patients

TL;DR: For patients requiring a prolonged ICU stay, the model of 24/7 in-house intensivist coverage was not associated with changes in ICU LOS, nor ICU and 30-day mortality, however a reduction in blood product use, ICU complications, and total hospital LOS was observed.
Journal ArticleDOI

Chemoradiotherapy versus radiotherapy alone in elderly patients with stage III non-small cell lung cancer: A systematic review and meta-analysis.

TL;DR: Treatment of stage III NSCLC patients 70 years or older with chemotherapy and radiotherapy is associated with improved overall survival compared to radiotherapy alone and CRT appears to be tolerable in fit elderly patients and represents a reasonable standard of clinical care.
Journal ArticleDOI

Resveratrol for adults with type 2 diabetes mellitus

TL;DR: The limited available research does not provide sufficient evidence to support any effect, beneficial or adverse, of four to five weeks of 10 mg to 1000 mg of resveratrol in adults with type 2 diabetes mellitus, and three RCTs reported that no adverse events were observed, indicating that no deaths occurred.
Journal ArticleDOI

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.

Cathrine Axfors, +230 more
TL;DR: In this article, the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials, were evaluated.